GSK3511294
Sponsors
Glaxosmithkline Research & Development Limited, GlaxoSmithKline
Conditions
AsthmaSevere asthma with an eosinophilic phenotype
Phase 1
First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma
CompletedNCT03287310
Start: 2017-10-17End: 2019-07-31Updated: 2021-03-01
Study of GSK3511294 in Healthy Chinese Participants
CompletedNCT05140200
Start: 2021-12-10End: 2022-12-23Updated: 2025-01-27
Phase 3
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
CompletedNCT04718103
Start: 2021-02-04End: 2024-04-11Updated: 2024-11-29
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 (depemokimab) compared with mepolizumab or benralizumab
CompletedCTIS2023-510230-84-00
Start: 2021-05-28End: 2025-09-10Target: 750Updated: 2025-10-27